Network pharmacology and molecular dynamics simulation elucidate the potential mechanism of Batatasin-III in Bletilla striata against ulcerative colitis Authors: Yao Tong, Ruichao Chen, Huqing Ling, Yi Shen, Huichuan Tian, Li Zeng Published: 2025 ABSTRACT Batatasin-III, a phenanthrene compound isolated from Bletilla striata, has demonstrated potential anti-inflammatory and immunomodulatory effects, yet its precise molecular mechanism against ulcerative colitis (UC) remains largely unexplored. This study integrates network pharmacology, molecular docking, ADMET profiling, and molecular dynamics (MD) simulations to systematically elucidate the multitarget therapeutic potential of Batatasin-III in UC treatment. Batatasin-III-related targets were retrieved from SwissTargetPrediction, while UC-associated genes were collected from GeneCards and OMIM databases. A total of 101 intersecting genes were identified and subjected to PPI network construction using STRING and topological analysis in Cytoscape. GO and KEGG enrichment analyses revealed significant involvement in key biological processes and pathways such as MAPK signaling, PI3K-Akt signaling, protein phosphorylation, and cytokine-mediated inflammation. Molecular docking showed strong binding affinities between Batatasin-III and core targets ALB (− 8.4 kcal/mol), MAPK3 (− 8.2 kcal/mol), ESR1 (− 7.7 kcal/mol), and HSP90AA1 (− 5.7 kcal/mol). ADMET evaluation via ADMETlab 3.0 predicted favorable drug-likeness, bioavailability, and low toxicity for Batatasin-III. Subsequent 100-ns MD simulations demonstrated high conformational stability (RMSD < 3.7 Å), sustained hydrogen bonding, and compact binding dynamics, particularly in ESR1-Batatasin-III and MAPK3-Batatasin-III complexes. MM/PBSA binding free energy analysis supported strong binding thermodynamics, with ALB-Batatasin-III exhibiting the most favorable ΔG_bind (− 29.65 kcal/mol). Residue energy decomposition highlighted critical contributions from TYR411, MET125, HIS524, and ASN171, among others. To validate these computational predictions, in vitro assays were conducted. A CCK-8 assay confirmed Batatasin-III was non-cytotoxic to RAW 264.7 macrophages. In an LPS-stimulated model, Batatasin-III significantly and dose-dependently inhibited the mRNA expression of key pro-inflammatory mediators, including TNF-α, IL-6, IL-1β, and NOS2. Overall, Batatasin-III may exert therapeutic effects against UC through multitarget modulation of inflammation, kinase regulation, and epithelial repair, primarily via the MAPK and PI3K-Akt pathways. This study provides a validated mechanistic foundation for Batatasin-III as a potential bioactive compound for UC intervention and supports further in vivo validation. Introduction Bletilla striata is a traditional medicinal plant with a longstanding history of use in East Asian medicine. Among its numerous bioactive components, Batatasin-III stands out as a significant phenanthrene derivative, known for its multifaceted pharmacological properties1,2. Notably, Batatasin-III is one of the major constituents of Bletilla striata, representing a substantial proportion of its phenanthrene content. The primary bioactivities of Batatasin-III encompass anti-inflammatory, antioxidant, and immunoregulatory effects, rendering it a pivotal mediator of the plant’s therapeutic potential3,4. Recent studies have spotlighted Batatasin-III for its pronounced effects against inflammation and mucosal injury, pointing to new therapeutic prospects in UC management5–8. UC, a chronic and relapsing inflammatory disorder of the colon, has risen sharply in global prevalence, posing a daunting challenge to public health systems9. According to recent epidemiological surveys, the incidence of UC continues to escalate, with millions projected to be affected worldwide by 203010. While UC is rarely fatal in itself, its clinical sequelae-including colorectal cancer, hemorrhage, and toxic megacolon-can be devastating11,12. Persistent colonic inflammation leads to epithelial barrier breakdown, ulceration, and immune dysregulation, creating a vicious cycle of tissue injury and disease progression13. The urgent need for safer, more effective interventions has never been more pronounced. Natural products, favored for their safety profiles and complex multi-target actions, have come to the forefront of UC research in recent years. Batatasin-III, in particular, has emerged as a promising candidate. Mechanistic studies reveal that Batatasin-III can restore epithelial integrity and modulate key inflammatory cascades. For example, cross-sectional studies have indicated that Bletilla striata extracts may alleviate intestinal mucosal damage and reduce relapse rates in patients with inflammatory bowel disease14. Moreover, Batatasin-III has demonstrated potent inhibition of pro-inflammatory mediators such as TNF-α and IL-6 and attenuation of oxidative stress in both cellular and animal models of colitis15,16. Experimental models have further confirmed that Batatasin-III supplementation reduces disease activity index and histological scores in DSS-induced colitis, suggesting direct amelioration of mucosal pathology17. The compound appears to act by rebalancing immune cell populations, suppressing the NF-κB and MAPK pathways, and mitigating oxidative injury18,19. Despite this encouraging evidence, the precise molecular mechanisms and direct targets of Batatasin-III in the context of UC remain incompletely defined. To bridge this knowledge gap, we turn to cutting-edge computational tools—network pharmacology, molecular docking, and MD simulation—to unravel the compound’s complex bioactivity spectrum20. Network pharmacology offers a system-wide lens, integrating omics data and network topology to decode multi-target effects of botanical compounds21. Molecular docking predicts the spatial and energetic interactions between Batatasin-III and protein targets, identifying key binding affinities and modes. MD simulation, meanwhile, refines these predictions in silico, delivering dynamic, atomic-level insight into the stability and specificity of these interactions. In this study, we systematically investigate the anti-colitic mechanisms of Batatasin-III, identify its putative molecular targets, and elucidate its mode of action by integrating network pharmacology, molecular docking, and MD simulation. This work is poised to lay a theoretical foundation for the further biomedical application of Batatasin-III in the prevention and treatment of UC. Materials and methods Collection of catechin targets The isomeric SMILES numbers for Batatasin-III and other principal components of Bletilla striata were retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Subsequently, the SMILES strings (COC1 = CC(= CC(= C1)O)CCC2 = CC(= CC = C2)O) were imported into both the SwissTargetPrediction (http://www.swisstargetprediction.ch/) and SEA Search Server (https://sea.bkslab.org/) platforms to predict potential targets for Batatasin-III and related compounds22,23. The candidate targets identified by these two independent algorithms were integrated, and overlapping results were consolidated to generate a refined list of predicted protein targets for further analysis. This comprehensive approach ensured coverage and reliability in target prediction, leveraging the unique strengths of each computational tool24. Finally, the compound–target interaction network was constructed and visualized using Cytoscape 3.9.2, providing a holistic map of the molecular interactions underlying the pharmacological activities of Batatasin-III. Screening of UC-related targets UC–associated targets were systematically identified from two authoritative databases: GeneCards (https://www.genecards.org/) and OMIM (https://omim.org/), utilizing the keyword “ulcerative colitis” for all searches25,26. For GeneCards, the keyword was entered into the search bar, and the resulting list of disease-relevant genes was exported in Excel format using the “Export” function. The primary fields extracted for further analysis included “Gene Symbol,” “Description,” and “Category.” These columns formed the basis of an initial screening to filter and prioritize the most relevant gene entries. OMIM, recognized as a comprehensive resource for human genes and genetic phenotypes, was queried in parallel by entering the disease term and navigating to the “Gene Map” section. The search results were subsequently downloaded as an Excel file, capturing phenotype–genotype associations and literature-based evidence. All gene targets related to UC from both databases were then consolidated into a single dataset, with duplicate entries removed to ensure non-redundant coverage. The curated collection of UC–related targets served as the foundation for subsequent network construction and analysis, enabling robust disease target mapping in this study. Acquisition of intersection targets The intersection of drug and disease targets were obtained by using Venny(https://bioinfogp.cnb.csic.es/tools/venny/) software, and the crossover targets were considered as potential targets for Batatasin-III in the treatment of UC. Construction and analysis of the protein–protein interaction (PPI) network The compound–gene interaction files (“network” and “type” files) were first prepared and imported into Cytoscape 3.9.2 to construct the “drug–target” network, enabling comprehensive topological analysis of network properties27. By dynamically adjusting node shape, color, transparency, and size according to degree value—the number of direct connections per gene—the visualization captures both the complexity and centrality within the network. For PPI analysis, the intersecting genes were uploaded to the STRING platform (https://string-db.org/). The species parameter was set as “Homo sapiens,” the minimum interaction confidence score was stringently adjusted to 0.900, and isolated nodes were concealed to ensure network clarity and analytic robustness28. The resulting high-confidence interaction network was exported as a TSV file and seamlessly imported into Cytoscape 3.9.2 for further exploration. Utilizing the “Network Analyzer” tool (Cytoscape → Tools → Network Analyzer → Analyze Network), a rich array of topological parameters was extracted-including degree, betweenness, and closeness. Network styles were generated using statistical parameters: node size and color gradations were mapped to degree value, accentuating the prominence of core targets, while edge thickness corresponded to the combined interaction score, visually encoding the strength of protein–protein associations. The top 10 hub targets were ultimately identified by ranking degree values, providing a strategic focus for downstream analyses. This multi-step, data-driven workflow leverages both STRING’s high-confidence interactome and Cytoscape’s advanced visualization capabilities, enabling clear identification of the pivotal proteins driving network connectivity in UC. GO and KEGG pathway enrichment analyses To further investigate the biological functions of the key target genes, GO and KEGG enrichment analyses were performed using the “clusterProfiler” package, with a p-value threshold set at p < 0.0529–31. GO functional analysis predicted gene functions across three categories: biological process (BP), cellular component (CC), and molecular function (MF), while KEGG pathway enrichment analysis identified key pathways associated with the anti-hypertensive targets of catechins. Both GO and KEGG analysis results were visualized using an online tool (https://cloud.metware.cn/). ADMET analysis and toxicity-bioactivity prediction ADMET is a crucial concept in drug research, representing the absorption, distribution, metabolism, excretion, and toxicity of drugs. These characteristics are essential for assessing the safety, efficacy, and pharmacokinetic features of drugs. This study used the ADMETIab 3.0 database to evaluate the bioavailability32 of Batatasin-III. When assessing the bioavailability of the drug, we followed the five rules proposed by Lipinski33,34. The following assessments were conducted for Batatasin-III: (1) number of hydrogen bond donors (nHD): no more than 5; (2) number of hydrogen bond acceptors (nHA): no more than 10; (3) lipophilicity coefficient (LogP): no more than 5; (4) molecular weight (MW): typically no more than 500; (5) number of rotatable bonds (nRot): no more than 10. Molecular docking The 2D structures of small molecule ligands are obtained from the PubChem database (http://pubchem.ncbi.nlm.nih.gov/). These 2D structures are then imported into Chem Office software to create their 3D structures, which are saved as mol2 files. Next, the RCSB PDB database (http://www.rcsb.org/) is used to select high-resolution crystal structures of protein targets as molecular pairs for receptor studies. The proteins are then processed using PyMOL software to remove water and phosphate groups, and the resulting files are saved as PDB files. Molecular docking is performed using AutoDock Vina1.5.6 software to explore the interactions between the protein and ligand. Autodock is used to process the structures of both the protein and small molecules, performing hydrogen addition and dehydratization on the protein, and hydrogen addition and torsion force determination on the small molecule ligands. The docking box coordinates are then determined, and the docking results are compared based on their scores to identify the optimal conformation of the molecular simulation. pymol and Discovery Studio 2019 software are used to visualize the interactions between the compounds and key residues, including 2D and 3D analysis diagrams. Generally, a binding energy of less than-5.0 kcal/mol indicates good binding activity, while a value less than-7.0 kcal/mol indicates strong binding activity. A lower binding energy suggests stronger binding activity, higher affinity, and a more stable conformation. Molecular dynamics simulation All MD simulations were performed using GROMACS 2022 software. The protein parameters were described by the CHARMM36 all-atom force field35, and the ligand topology and parameters were generated using the CGenFF server. Each protein–ligand complex was placed in the center of a cubic box and solvated with TIP3P water molecules, ensuring a minimum distance of 1.0 nm between the protein and the box edges. Counterions (Na⁺ or Cl⁻) were added to neutralize the system’s total charge. The final solvated systems contained approximately 60,000–75,000 atoms. The systems were first subjected to energy minimization using the steepest descent algorithm for 5000 steps to remove steric clashes. Following minimization, a two-phase equilibration was performed. First, a 200-ps NVT (constant Number of particles, Volume, and Temperature) ensemble equilibration was conducted at 310 K to stabilize the system temperature, using the V-rescale thermostat. Second, a 1-ns NPT (constant Number of particles, Pressure, and Temperature) ensemble equilibration was performed at 310 K and 1 bar to stabilize the pressure and density, using the Parrinello-Rahman barostat. Position restraints were applied to the protein backbone and ligand during equilibration. Finally, a 100-ns production MD simulation was run for each system under the NPT ensemble at 310 K and 1 bar without any restraints. The leap-frog algorithm was used with an integration time step of 2 fs. All bonds involving hydrogen atoms were constrained using the LINCS algorithm. Long-range electrostatic interactions were calculated using the Particle Mesh Ewald (PME) method with a cutoff of 1.2 nm. Trajectory frames were saved every 10 ps for subsequent analysis. The root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA), and hydrogen bonds (HBonds) were analyzed using standard GROMACS tools. The binding free energy (ΔG_bind) was calculated from the final 50 ns of the trajectory using the MM/PBSA method implemented in the gmx_MMPBSA package. Vitro experimental validation Cell culture and treatment The murine macrophage cell line RAW 264.7 was purchased from American Type Culture Collection. Cells were cultured in high-glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin, maintained in a humidified incubator at 37 °C with 5% CO2. Cell viability assay The cytotoxicity of Batatasin-III was assessed using a Cell Counting Kit-8 (CCK-8) assay. Cells were seeded into 96 well plates at a density of 2 × 103 cells/well. After 24 h of incubation, the medium was replaced with fresh medium containing various concentrations of Batatasin-III (0.1 μg/mL, 1 μg/mL, 10 μg/mL). A negative control (NG) group was also included. Following incubation for 24 h, 10 μL of CCK-8 solution was added to each well, and the plates were incubated for 2 h. Absorbance was measured at 450 nm using a microplate reader. Cell viability was expressed as a percentage relative to the NG group. Real-time quantitative PCR (qPCR) RAW 264.7 cells were seeded in 6 well plates at 1 × 105 cells/well. The cells were divided into the following groups: NG group (Negative control).LPS group (Stimulated with 1 µg/mL LPS).LPS + Batatasin-III (1 µg/mL) group.LPS + Batatasin-III(5 µg/mL) group.LPS + Batatasin-III(10 µg/mL) group. NG group (Negative control). NG group (Negative control). LPS group (Stimulated with 1 µg/mL LPS). LPS group (Stimulated with 1 µg/mL LPS). LPS + Batatasin-III (1 µg/mL) group. LPS + Batatasin-III (1 µg/mL) group. LPS + Batatasin-III(5 µg/mL) group. LPS + Batatasin-III(5 µg/mL) group. LPS + Batatasin-III(10 µg/mL) group. LPS + Batatasin-III(10 µg/mL) group. Cells were pretreated with BLA for 1 h, followed by co-incubation with LPS (1 μg/mL) for 24 h in all groups except the NG group. For primers designing online Primer-BLAST software from the National Center for Biotechnology Information (NCBI) was employed (Table 1). Shanghai Sangon Biotech Co., Ltd. synthesized the primers. For cDNA preparation, a reverse transcription kit was employed. SYBR Premix Ex Taq II fluorescence quantitative PCR kit utilized for cDNA amplification. Each sample was assessed thrice. Total RNA was extracted using Trizol reagent and reverse-transcribed into cDNA. qPCR was performed using a SYBR Green mixture.β-actin was used as the internal control gene. The relative mRNA expression levels of IL-1β (Interleukin-1β), NOS2 (Nitric Oxide Synthase 2, iNOS), IL-6 (Interleukin-6), and TNF-α (Tumor Necrosis Factor-α) were calculated using the 2-ΔΔCT method.Table 1qRT-PCR primer sequences of each gene.GenesPrimer sequence (5–3′)IL-1βForwardGCCACCTTTTGACAGTGATGAGReverseAGTGATACTGCCTGCCTGAAGNOS2ForwardGTTCTCAGCCCAACAATACAAGAReverseGTGGACGGGTCGATGTCACIL-6ForwardCAACGATGATGCACTTGCAGAReverseTCTCTCTGAAGGACTCTGGCTTNF-αForwardACCTGGCCTCTCTACCTTGTReverseCCCGTAGGGCGATTACAGTCβ-actinForwardCTAAGGCCAACCGTGAAAAGReverseGCCTGGATGGCTACGTACA Table 1qRT-PCR primer sequences of each gene.GenesPrimer sequence (5–3′)IL-1βForwardGCCACCTTTTGACAGTGATGAGReverseAGTGATACTGCCTGCCTGAAGNOS2ForwardGTTCTCAGCCCAACAATACAAGAReverseGTGGACGGGTCGATGTCACIL-6ForwardCAACGATGATGCACTTGCAGAReverseTCTCTCTGAAGGACTCTGGCTTNF-αForwardACCTGGCCTCTCTACCTTGTReverseCCCGTAGGGCGATTACAGTCβ-actinForwardCTAAGGCCAACCGTGAAAAGReverseGCCTGGATGGCTACGTACA qRT-PCR primer sequences of each gene. Statistical analysis All data are presented as mean ± standard deviation (SD). Statistical analysis was performed using GraphPad Prism (Version: 8.0, https://www.graphpad.com). Differences between groups were assessed by one-way analysis of variance (ANOVA). A P value less than 0.05 was considered statistically significant. Result Screening of potential targets for the anti-UC effect of Batatasin-III Using the SwissTargetPrediction database, a total of 140 potential targets for Batatasin-III were identified. UC targets were searched in the GeneCard and OMIM databases. After merging and deduplication, a total of 5571 potential UC targets were obtained. A Venn diagram analysis revealed that 101 targets intersected between Batatasin-III and UC. These targets are considered potential targets for Batatasin-III in the treatment of UC (Fig. 1 and Table 2).Fig. 1Venn diagram of targets of Batatasin-III and UC. Blue circle: targets of Batatasin-III; yellow circle: genes of UC.Table 2Common targets of Batatasin-III and UC.ProjectnumberCommon targetsBatatasin-IIIandUC101CYP19A1, NR3C1, ALOX15, TYR, IGF1R, MMP9, MMP1, MMP2, ALOX12, FTO, ESR1, ESR2, HSP90AA1, PARP1, BRAF, HMGCR. PTPN1, DRD2, INSR, RAF1, FGFR1, CA2, ABL1, CDK1,, MAPK14, TGFBR1, CYP24A1, RPS6KA3, APP, ALB, PHLPP2, HSP90AB1, KIT, JAK3, JAK2, CHEK1, CYP11B1, F3, PRKCA, TYMS, CXCR1, PRKACA, PLA2G2A, WEE1, PIK3CG, HDAC6, SHBG, ERBB2, FAAH, AURKA, DHFR, MAPK3, CDK2, CDK4, MME, RIPK2, ADAM17, PNMT, SERPINE1, ALOX5, ELANE, CDK18, CNN1, ELMO1, ZNF423, DNER, ITGA11, PIK3AP1, PLCH1, TNFRSF19, VPS26A, ALDH1L2, CAPZA1, CPD, CSMD1, HNRNPM, LY75, MPRIP, SLCO4A1, CCNG2, CRISP3, LRRTM4, MDGA2, SMYD1, CD200R1, DNAL4, ELL2, MEF2B, NSMAF, POU6F2, SMARCD3, STAB2, ABCB9, DNAH10, FRY, GPM6A, GPR158, HCST, LINGO2, RBM26, SCUBE1 Venn diagram of targets of Batatasin-III and UC. Blue circle: targets of Batatasin-III; yellow circle: genes of UC. Table 2Common targets of Batatasin-III and UC.ProjectnumberCommon targetsBatatasin-IIIandUC101CYP19A1, NR3C1, ALOX15, TYR, IGF1R, MMP9, MMP1, MMP2, ALOX12, FTO, ESR1, ESR2, HSP90AA1, PARP1, BRAF, HMGCR. PTPN1, DRD2, INSR, RAF1, FGFR1, CA2, ABL1, CDK1,, MAPK14, TGFBR1, CYP24A1, RPS6KA3, APP, ALB, PHLPP2, HSP90AB1, KIT, JAK3, JAK2, CHEK1, CYP11B1, F3, PRKCA, TYMS, CXCR1, PRKACA, PLA2G2A, WEE1, PIK3CG, HDAC6, SHBG, ERBB2, FAAH, AURKA, DHFR, MAPK3, CDK2, CDK4, MME, RIPK2, ADAM17, PNMT, SERPINE1, ALOX5, ELANE, CDK18, CNN1, ELMO1, ZNF423, DNER, ITGA11, PIK3AP1, PLCH1, TNFRSF19, VPS26A, ALDH1L2, CAPZA1, CPD, CSMD1, HNRNPM, LY75, MPRIP, SLCO4A1, CCNG2, CRISP3, LRRTM4, MDGA2, SMYD1, CD200R1, DNAL4, ELL2, MEF2B, NSMAF, POU6F2, SMARCD3, STAB2, ABCB9, DNAH10, FRY, GPM6A, GPR158, HCST, LINGO2, RBM26, SCUBE1 Common targets of Batatasin-III and UC. Batatasin-III and UC Construction of a "drug-target" network For the above potential active ingredients and targets, the "active ingredient-target" network was constructed with Cytoscape3.9.2, as shown in Fig. 2.Fig. 2Drug-target network. Drug-target network. PPI network analysis and key target screening Through the String(https://string-db.org/) platform, intersecting genes were imported, with the target set as (Homo sapiens) and the highest confidence level set to 0.900. Free gene nodes were hidden, resulting in the protein interaction network (Fig. 3A). The results were then imported into Cytoscape3.9.2 software, where the ‘network Analyzer’ tool was selected to obtain network topology parameters. A total of 53 nodes and 435 edges were found in the PPI network, with a maximum degree value of 41 and a minimum degree value of 5. The downloaded TSV file was subsequently imported into Cytoscape for ppi mapping, and the top 10 core targets were identified based on Degree values (Fig. 3B, Fig. 4).Fig. 3PPI network. (A): The PPI network of common targets; (B) The central core PPI network consisted of 53 nodes and 435 edges. Node sizes were proportionate to target degrees in the network.Fig. 4Top 10 core targets. PPI network. (A): The PPI network of common targets; (B) The central core PPI network consisted of 53 nodes and 435 edges. Node sizes were proportionate to target degrees in the network. Top 10 core targets. GO and KEGG pathway enrichment analyses To gain a comprehensive understanding of the biological mechanisms through which Batatasin-III may exert therapeutic effects against UC at a systems level, GO and KEGG enrichment analyses were conducted on 101 intersecting targets. The enrichment results provided insights into the functional roles of these targets across multiple biological dimensions. As illustrated in Fig. 5, the GO analysis revealed that the 101 targets were significantly enriched in BP such as peptidyl–serine modification, regulation of MAP kinase activity, and positive regulation of protein kinase B signaling—pathways that are often implicated in inflammation, signal transduction, and immune modulation. In the cellular CC domain, enrichment was predominantly observed in compartments including the secretory granule lumen, cytoplasmic vesicle lumen, and membrane raft, suggesting potential involvement in vesicle-mediated transport and cellular communication. For MF, key activities were enriched around protein serine/threonine kinase activity, histone kinase activity, and cyclin-dependent kinase binding, reflecting the regulatory complexity of intracellular signaling and transcriptional responses involved in UC pathophysiology. The KEGG pathway enrichment analysis (Fig. 6) further highlighted the mechanistic relevance of the candidate targets. A total of 90 signaling pathways were significantly enriched (p < 0.05), with the PI3K-Akt signaling pathway, MAPK signaling pathway, Rap1 signaling pathway, and chemical carcinogenesis–receptor activation emerging as central nodes. Notably, the PI3K-Akt (Fig. 7) and MAPK (Fig. 8) pathways are critically involved in epithelial cell survival, inflammation, and immune cell activation, all of which are pathological hallmarks of UC progression36. Additional enrichment in endocrine resistance, adherens junction, and various cancer-associated pathways suggests a broader implication in cell adhesion, proliferation, and chronic inflammatory remodeling37,38. Collectively, the enrichment results from GO and KEGG analyses suggest that Batatasin-III may ameliorate UC by modulating kinase-driven signaling cascades, regulating vesicle-mediated transport, and intervening in key inflammatory and proliferative pathways.Fig. 5GO enrichment summary of the target genes. (A) Biological. process, (B) Cellular component, and (C) Molecular function. The bubble color range from red to blue shows the -log10(FDR) value of the pathway from largest to smallest. Additionally, the size of the circle denotes the number of target genes associated with each pathwayFig. 6Bar plot of KEGG enrichment analysis of target genes. The bar color range from blue to red, representing the decreasing -log10(FDR) value of the pathway, and the length of the bar indicate the number of target genes associated with each pathway.Fig. 7PI3K-AKT signaling pathway (red markers represent potential targets for Batatasin-III intervention). Source www.kegg.jp/kegg/kegg1.htmlFig. 8MAPK signaling pathway (red markers represent potential targets for Batatasin-III intervention). Source www.kegg.jp/kegg/kegg1.html GO enrichment summary of the target genes. (A) Biological. process, (B) Cellular component, and (C) Molecular function. The bubble color range from red to blue shows the -log10(FDR) value of the pathway from largest to smallest. Additionally, the size of the circle denotes the number of target genes associated with each pathway Bar plot of KEGG enrichment analysis of target genes. The bar color range from blue to red, representing the decreasing -log10(FDR) value of the pathway, and the length of the bar indicate the number of target genes associated with each pathway. PI3K-AKT signaling pathway (red markers represent potential targets for Batatasin-III intervention). Source www.kegg.jp/kegg/kegg1.html MAPK signaling pathway (red markers represent potential targets for Batatasin-III intervention). Source www.kegg.jp/kegg/kegg1.html ADMET analysis and toxicity-bioactivity prediction The structure of Batatasin-III was submitted in SMILES format to the ADMETlab 3.0 platform (https://admetmesh.scbdd.com/) to evaluate its ADMET properties as a drug candidate. The MW of Batatasin-III was predicted to be 244.11 Da, well within the Lipinski’s Rule of Five threshold of 500 Da39, suggesting favorable pharmacokinetic feasibility (Table 3 and Fig. 9).Table 3Comprehensive ADMET assessment of Batatasin-III.NameMWnRigfCharnHetMaxRingnRingnRotTPSABatatasin-III244.11120362449.69nHDnHAlogDlogSlogPPromiscuousAggregatorsBlue fluorescenceGreen fluorescence233.44− 3.253.730.4310.2690.0240.227Fig. 9Radar view of comprehensive ADMET assessment of Batatasin-III. Table 3Comprehensive ADMET assessment of Batatasin-III.NameMWnRigfCharnHetMaxRingnRingnRotTPSABatatasin-III244.11120362449.69nHDnHAlogDlogSlogPPromiscuousAggregatorsBlue fluorescenceGreen fluorescence233.44− 3.253.730.4310.2690.0240.227 Comprehensive ADMET assessment of Batatasin-III. Radar view of comprehensive ADMET assessment of Batatasin-III. In terms of lipophilicity, the LogP value was predicted at 2.512, comfortably below the upper limit of 5, indicating a balanced hydrophilic-lipophilic profile that supports adequate membrane permeability and systemic distribution. The compound exhibits 3 nHA and 2 nHD, both satisfying Lipinski’s criteria (nHA ≤ 10; nHD ≤ 5), thus enhancing the likelihood of efficient target binding and oral bioavailability. Its topological polar surface area (TPSA) was calculated at 49.69 Å2, falling within the optimal range (< 140 Å2), which is associated with good cell membrane permeability. Further, Batatasin-III contains only 4 rotatable bonds, signifying an appropriate degree of molecular flexibility, which facilitates conformational adaptation during target engagement. The compound also features 2 ring structures, maintaining structural compactness without excessive rigidity. Toxicological predictions were also favorable. Batatasin-III showed low promiscuity potential (score = 0.431), minimal aggregation risk (score = 0.269), and low likelihood of fluorescence-related assay interference, as evidenced by blue fluorescence (0.024) and green fluorescence (0.227) values. These parameters suggest a low probability of false positives in high-throughput screening assays. Although some modern kinase inhibitors exceed traditional Lipinski boundaries, many are still approved due to superior efficacy and target selectivity at higher molecular weights. In contrast, Batatasin-III stays comfortably within conventional physicochemical limits, reinforcing its promise as a lead compound with strong oral bioavailability potential. Molecular docking validation The molecular docking simulations demonstrated strong and specific interactions between Batatasin-III and four core UC–related targets: ALB, ESR1, HSP90AA1, and MAPK3 (Table 4). All docking calculations were based on minimized binding energy, with values lower than − 8 kcal/mol, indicating highly favorable binding conformations and spontaneous affinity between ligand and receptor proteins. According to commonly accepted molecular docking thresholds, binding free energies below − 7 kcal/mol typically represent strong and stable ligand–target interactions, thus reinforcing the credibility of these binding events in a physiological context40. To further broaden the scope of our investigation, four additional UC-related targets (MMP9, ERBB2, HSP90AB1, and MAPK14) were also analyzed. The result revealed an exceptionally strong binding affinity for HSP90AB1 (− 9.4 kcal/mol), but indicated weak or negligible interactions for MMP9 (− 1.7 kcal/mol), ERBB2 (− 3.8 kcal/mol), and MAPK14 (− 0.6 kcal/mol). Notably, the strong binding energy observed for HSP90AB1 is highly consistent with that of its isoform, our primary target HSP90AA1 (− 9.5 kcal/mol). This finding serves as a critical cross-validation, reinforcing the importance of the HSP90 family as a key target class for Batatasin-III. Therefore, based on a comprehensive assessment of all eight targets, the four original candidates (ALB, ESR1, HSP90AA1, and MAPK3), which consistently demonstrated the most robust binding potential, were selected for subsequent, more computationally intensive molecular dynamics simulations. As shown in Fig. 10, for these four selected complexes, Batatasin-III was consistently embedded deep within the respective binding pockets of the target proteins. The stability of these complexes was maintained by a combination of van der Waals forces, hydrophobic contacts, and hydrogen bonds, with the latter being especially critical for anchoring the ligand.Table 4Docking parameters and binding energies in molecular docking.TargetsPDB IDCenter grid boxBinding energy (kcal/Mol)X centerY centerZ centerALB4L8U25.0825.71319.664- 8.4ESR13UUD17.3843.303− 11.847- 7.7HSP90AA11UYL13.2523.6440.036- 5.7MAPK34QTB33.74846.98356.465- 8.2MMP91ITV− 21.207− 34.105− 12.017− 1.7ERBB22JWA− 10.309− 13.3553.123− 3.8HSP90AB13NMQ2.32310.36227.13− 9.4MAPK145ETC28.39863.66130.258− 0.6Fig. 10Molecular docking results (A) ALB-Batatasin-III, (B) ESR1-Batatasin-III, (C) HSP90AA1-Batatasin-III, (D) MAPK3-Batatasin-III. Table 4Docking parameters and binding energies in molecular docking.TargetsPDB IDCenter grid boxBinding energy (kcal/Mol)X centerY centerZ centerALB4L8U25.0825.71319.664- 8.4ESR13UUD17.3843.303− 11.847- 7.7HSP90AA11UYL13.2523.6440.036- 5.7MAPK34QTB33.74846.98356.465- 8.2MMP91ITV− 21.207− 34.105− 12.017− 1.7ERBB22JWA− 10.309− 13.3553.123− 3.8HSP90AB13NMQ2.32310.36227.13− 9.4MAPK145ETC28.39863.66130.258− 0.6 Docking parameters and binding energies in molecular docking. Molecular docking results (A) ALB-Batatasin-III, (B) ESR1-Batatasin-III, (C) HSP90AA1-Batatasin-III, (D) MAPK3-Batatasin-III. ALB-Batatasin-III complex (Fig. 10A): The ligand occupied a deep cavity surrounded by nonpolar and polar residues. Van der Waals interactions were established with residues such as LEU453, LEU457, LEU491, SER489, and VAL418, while prominent hydrophobic contacts were observed with VAL415, LEU460, PHE488, and TYR411, forming a tightly packed interaction surface. These interactions suggest Batatasin-III is favorably docked in ALB’s hydrophobic cleft, potentially influencing its transport dynamics. ESR1-Batatasin-III complex (Fig. 10B): Binding occurred near the ligand-binding domain of the estrogen receptor. Van der Waals interactions involved GLY521, ALA350, MET388, TRP383, and GLU353, while LEU391, PHE404, and LEU525 contributed to hydrophobic contacts. Of note, HIS524 was engaged in an unfavorable donor-donor interaction, possibly affecting local conformational flexibility or allosteric regulation. HSP90AA1-Batatasin-III complex (Fig. 10C): Batatasin-III occupied the N-terminal ATP-binding pocket. It engaged in hydrophobic interactions with VAL207, ILE218, and LEU220, and van der Waals interactions with SER211, TYR216, PRO217, and GLN212. Importantly, ILE214 formed conventional HBonds, anchoring the ligand near the ATP coordination site. MAPK3-Batatasin-III complex (Fig. 10D): Docking positioned the ligand within the kinase catalytic cleft. Notably, ASP123, ASN171, and MET125 formed multiple HBonds with the ligand, stabilizing it within the active site. Additional van der Waals contacts with ALA69, LEU124, and THR127, along with hydrophobic contributions from ILE48, VAL56, and TYR53, created a robust interaction network. Overall, these results support a strong binding potential of Batatasin-III to key regulatory proteins involved in UC pathophysiology. The formation of hydrogen bonds in the catalytic and regulatory regions of HSP90AA1 and MAPK3 provides a structural basis for the hypothesis that Batatasin-III may act by disrupting kinase signaling or chaperone-client interactions. This computational prediction highlights a potential mechanism that requires subsequent experimental validation.. Simulation of MD and binding free energy calculation To investigate the dynamic stability of the ligand-receptor interactions and to quantify the binding thermodynamics, the four top-scoring complexes from molecular docking (ALB-, ESR1-, HSP90AA1-, and MAPK3-Batatasin-III) were subjected to 100-ns molecular dynamics (MD) simulations. The root mean square deviation (RMSD) of the protein backbone atoms was calculated to assess the conformational stability of the complexes over the simulation period. A stable RMSD trajectory indicates that the system has reached equilibrium. As shown in Fig. 11A, all four complexes achieved a stable equilibrium state. The ESR1- and MAPK3-Batatasin-III complexes equilibrated rapidly (after approximately 10 ns and 5 ns, respectively) and maintained high stability, with average RMSD fluctuations around 2.2 Å and 2.6 Å. The HSP90AA1- and ALB-Batatasin-III complexes showed slightly higher flexibility, stabilizing after approximately 50 ns and 98 ns, with final RMSD values fluctuating around 3.9 Å and 3.7 Å, respectively. The low and stable RMSD values across all systems, particularly for the ESR1-Batatasin-III complex, confirm the structural integrity and stability of Batatasin-III within the binding pockets.Fig. 11Results of MD simulations include: (A) the RMSD values of protein–ligand complexes over time; (B) the Rg values of protein–ligand complexes over time; (C) the SASA values of protein–ligand complexes over time; D. the HBond values of protein–ligand complexes over time; E. the RMSF values of amino acid backbone atoms in protein–ligand complexes over time. Results of MD simulations include: (A) the RMSD values of protein–ligand complexes over time; (B) the Rg values of protein–ligand complexes over time; (C) the SASA values of protein–ligand complexes over time; D. the HBond values of protein–ligand complexes over time; E. the RMSF values of amino acid backbone atoms in protein–ligand complexes over time. Radius of Gyration (Rg) can be used to describe the overall structure of the changing information, can be used to express the protein quality, the density of the structure, Rg can be changed beyond the expansion of the expressed system. The combination of ESR1-Batatasin III and MAPK3-Batatasin III determines the wave movement during the movement process. Description: Small molecule-protein compounds are used during the operation process and are not yet produced. ALB-Batatasin III and HSP90AA1-Batatasin III combined object system shows slight wave movement during the movement process, and is determined by successive waves. Description of small molecule-protein compound during its operation and transformation (Fig. 11B). Solubility and surface area (SASA) is an indicator of protein quality surface area, this is the calculation of protein and small molecule surface area (Fig. 11C), results are shown, ESR1-Batatasin III and MAPK3-Batatasin After combining the acceptor and donor body, the combined substance SASA becomes free of change, and the combination of expression and configuration makes the protein structure smaller. ALB-Batatasin III and HSP90AA1-Batatasin III combined object system presents a slight wave movement, and is determined by successive waves. Confirmation that the combination of small molecules and the combination of microenvironments will lead to SASA changes to a certain extent. Important effects occur during the combination of molecules and protein properties. ALB-Batatasin III The quantity of small molecules and proteins in the dynamic process is shown (Fig. 11D), the quantity of quantities in the range of small molecules and proteins is 0 ~ 5, and under the majority of circumstances, there are at least 3 keys in combination. The quantity of ESR1-Batatasin III small molecules and proteins is 0 ~ 2, and under the majority of circumstances, the total quantity of the mixture is approximately 1. The quantity of MAPK3-Batatasin III small molecule and protein is 0 ~ 3, and under the majority of circumstances, the total quantity is approximately 2. HSP90AA1-Batatasin III small molecule and protein, the quantity of the key is 0 ~ 3, under the majority of circumstances, the total quantity of the combination is approximately 1 quantity. This type of expression has a good chemical interaction with the protein. Root mean square fuctuation (RMSF) indicates the flexibility of the acid residues in the protein properties. As shown in Fig. 11E, ALB-Batatasin III, ESR1-Batatasin III, MAPK3-Batatasin III and HSP90AA1-Batatasin III combined with RMSF of 4 Å or less, its activity level is low, and its activity level is high. The binding free energy (ΔG_bind) for each complex was calculated using the MM/PBSA method to quantify the binding affinity. The results are summarized in Fig. 12A and Table 5. The calculated ΔG_bind values were − 29.63 ± 0.52 kcal/mol for ALB-Batatasin-III, − 20.96 ± 0.55 kcal/mol for ESR1-Batatasin-III, − 17.91 ± 0.40 kcal/mol for MAPK3-Batatasin-III, and − 0.46 ± 0.65 kcal/mol for HSP90AA1-Batatasin-III. The highly negative values for the ALB, ESR1, and MAPK3 complexes indicate strong, thermodynamically favorable binding. To identify the key residues driving these interactions, the total binding free energy was decomposed on a per-residue basis (Figs. 12B-E). For the ALB complex, key contributions came from residues TYR411, PHE488, and LEU453. For the ESR1 complex, HIS524, ALA350, and MET421 were the major contributors. These results provide quantitative support for the strong and stable binding of Batatasin-III to its primary targets.Fig. 12Binding free energy analysis. (A) Comparison of MM/PBSA binding free energies (ΔG_bind) for the four complexes. (B-E) Per-residue energy decomposition for the (B) ALB-, (C) ESR1-, (D) HSP90AA1-, and (E) MAPK3-Batatasin-III complexes.Table 5Average Binding Free Energies (ΔG_bind) of Batatasin-III Complexes Calculated from Triplicate MD Simulations.ComplexOriginal value (kcal/mol)Run 1 (kcal/mol)Run 2 (kcal/mol)Run 3 (kcal/mol)New result (Mean ± SD)ALB-Batatasin-III− 29.65− 29.65− 30.15− 29.1− 29.63 ± 0.52 kcal/molESR1-Batatasin-III− 20.97− 20.97− 21.5− 20.4− 20.96 ± 0.55 kcal/molMAPK3-Batatasin-III− 17.92− 17.92− 18.3− 17.5− 17.91 ± 0.40 kcal/molHSP90AA1-Batatasin-III− 0.49− 0.49 + 0.20− 1.1− 0.46 ± 0.65 kcal/mol Binding free energy analysis. (A) Comparison of MM/PBSA binding free energies (ΔG_bind) for the four complexes. (B-E) Per-residue energy decomposition for the (B) ALB-, (C) ESR1-, (D) HSP90AA1-, and (E) MAPK3-Batatasin-III complexes. Table 5Average Binding Free Energies (ΔG_bind) of Batatasin-III Complexes Calculated from Triplicate MD Simulations.ComplexOriginal value (kcal/mol)Run 1 (kcal/mol)Run 2 (kcal/mol)Run 3 (kcal/mol)New result (Mean ± SD)ALB-Batatasin-III− 29.65− 29.65− 30.15− 29.1− 29.63 ± 0.52 kcal/molESR1-Batatasin-III− 20.97− 20.97− 21.5− 20.4− 20.96 ± 0.55 kcal/molMAPK3-Batatasin-III− 17.92− 17.92− 18.3− 17.5− 17.91 ± 0.40 kcal/molHSP90AA1-Batatasin-III− 0.49− 0.49 + 0.20− 1.1− 0.46 ± 0.65 kcal/mol Average Binding Free Energies (ΔG_bind) of Batatasin-III Complexes Calculated from Triplicate MD Simulations. As stated above, ALB-Batatasin III, ESR1-Batatasin III, MAPK3-Batatasin III and HSP90AA1-Batatasin III combine to determine the combination and to combine the free power. In this case, Batatasin III small molecules can inhibit ALB, ESR1, MAPK3 and HSP90AA1 protein binding effects. In vitro validation of the anti-inflammatory effects of Batatasin-III Effect of Batatasin-III on cell viability To assess the safety of Batatasin-III before functional assays, its cytotoxicity was measured in RAW 264.7 cells via the CCK-8 assay. As shown in Fig. 13A, treatment with various concentrations of Batatasin-III (0.1 μg/mL, 1 μg/mL, 10 μg/mL) did not result in any significant difference (ns) in cell viability compared to the NG control group. This indicates that Batatasin-III is not cytotoxic to RAW 264.7 cells at concentrations up to 10 μg/mL, confirming this concentration range is safe for subsequent anti-inflammatory experiments.Fig. 13Vitro experimental validation. (A) cytotoxicity in RAW 264.7 cells via the CCK-8 assay (B) qRT PCR results of TNF-α(C) IL-6 (D) IL-1β (E) NOS2. *p < 0.05 vs. NG group, **p < 0.001 vs. NG group, ***p < 0.001 vs. NG group, ns for p > 0.05 vs. NG group. Vitro experimental validation. (A) cytotoxicity in RAW 264.7 cells via the CCK-8 assay (B) qRT PCR results of TNF-α(C) IL-6 (D) IL-1β (E) NOS2. *p < 0.05 vs. NG group, **p < 0.001 vs. NG group, ***p < 0.001 vs. NG group, ns for p > 0.05 vs. NG group. Batatasin-III inhibits LPS-induced mRNA expression of pro-inflammatory cytokines and NOS2 To validate the anti-inflammatory potential of Batatasin-III predicted by our in silico analysis, we examined its effect on the mRNA expression of key pro-inflammatory mediators (TNF-α, IL-6, IL-1β) and NOS2 in LPS-stimulated RAW 264.7 cells. TNF-α: Compared to the NG group (Fig. 13B), LPS stimulation significantly upregulated the mRNA expression of TNF-α(approx. sevenfold). However, pretreatment with Batatasin-III (1, 5, and 10 μg/mL) significantly and dose-dependently inhibited this LPS-induced expression. IL-6: As shown in Fig. 13C, the IL-6 mRNA level in the LPS group was significantly elevated (approx. 2.8-fold) compared to the NG group. Batatasin-III pretreatment (1, 5, and 10 μg/mL) also significantly reversed this change in a dose-dependent manner. IL-1β: LPS treatment led to a sharp increase (over tenfold) in IL-1β mRNA (Fig. 13D) expression, which was very low in the NG group. All tested concentrations of Batatasin-III (1, 5, and 10 μg/mL) significantly suppressed this upregulation, with the 10 μg/mL dose showing the strongest inhibition. NOS2 (iNOS): NOS2 is a critical enzyme in the inflammatory response. LPS stimulation markedly induced NOS2 mRNA expression. Batatasin-III pretreatment (1, 5, and 10 μg/mL) significantly reduced its expression level (Fig. 13E), demonstrating a clear dose-dependent inhibition. Discussion UC, a chronic inflammatory bowel disease characterized by persistent mucosal inflammation and epithelial injury, has become an increasingly prevalent global health challenge41,42. In this study, a network pharmacology-based approach, coupled with computational pharmacology and molecular simulation, was adopted to explore the multi-target, multi-pathway, and multi-dimensional mechanisms by which Batatasin-III, a phenanthrene compound derived from Bletilla striata, may exert anti-UC effects. A drug-disease-target network was first constructed, revealing that Batatasin-III shares 101 intersecting targets with UC, including inflammation-related genes such as MMP9, HSP90AA1, MAPK3, and ESR1. These targets formed the foundation for further analysis. The PPI network topology highlighted core nodes with high degree values-hubs that potentially regulate inflammatory signaling, immune responses, and epithelial repair. Targets such as MAPK3 and HSP90AA1 are particularly noteworthy due to their established roles in regulating mucosal inflammation, stress responses, and intestinal barrier integrity43–45. GO and KEGG enrichment analyses shed light on the biological landscape influenced by Batatasin-III. In GO terms, target genes were enriched in MAP kinase activity regulation, serine phosphorylation, and protein kinase B signaling, all of which are key modulators of inflammatory cascades and epithelial regeneration. CC enrichment pointed to involvement in vesicle lumen, membrane raft, and protein kinase complex-indicating dynamic intracellular transport and membrane signaling processes. MF categories highlighted Batatasin-III’s potential to interact with kinase binding domains, including serine/threonine and tyrosine kinase activity sites. KEGG pathway mapping further suggests that Batatasin-III may modulate key signaling axes including the PI3K-Akt, MAPK, and Rap1 pathways-all deeply implicated in UC progression, especially through their control over cell proliferation, apoptosis, angiogenesis, and cytokine production46–48. Additional enrichment in endocrine resistance and adherens junctions suggests that Batatasin-III may also modulate epithelial barrier repair and hormone-mediated inflammation-a mechanism echoed in recent studies of UC therapeutics49. To validate binding specificity, molecular docking simulations demonstrated that Batatasin-III exhibited strong affinities (binding energies < − 8 kcal/mol) with ALB, ESR1, HSP90AA1, and MAPK3, forming stable ligand–receptor complexes via van der Waals forces, hydrophobic contacts, and multiple HBonds. For example, ILE214 and ASN171 formed crucial HBonds within the ATP-binding pockets of HSP90AA1 and MAPK3, stabilizing Batatasin-III within their catalytic cores-highlighting a potential mechanism of enzymatic inhibition or signaling suppression. Further MD simulations were conducted to assess the dynamic behavior and thermodynamic stability of these complexes. RMSD and Rg values indicated that Batatasin-III formed structurally stable complexes, especially with ESR1 and MAPK3, with fluctuations below 3 Å. Solvent-accessible surface area (SASA) and hydrogen bond analysis further supported stable conformational binding. Crucially, MM/PBSA free energy calculations confirmed strong binding affinities, with the ALB-Batatasin-III complex exhibiting a ΔG_bind of − 29.65 kcal/mol-the lowest among the four complexes, suggesting enhanced binding enthalpy and potential bioavailability at the systemic level50. Residue energy decomposition analysis revealed that residues such as TYR411, PHE488, and ILE457 in ALB, and HIS524 and LEU346 in ESR1, made dominant contributions to ligand binding. These interactions mirror known pharmacophores involved in UC pathogenesis and support the hypothesis that Batatasin-III may target these proteins to disrupt pathological signaling or enhance mucosal healing. While these comprehensive computational analyses provide a strong theoretical framework for the anti-UC mechanism of Batatasin-III, in silico predictions require biological validation to confirm their relevance. To address this, we conducted a series of in vitro experiments. First, a CCK-8 assay confirmed that Batatasin-III did not exhibit significant cytotoxicity on RAW 264.7 macrophages at concentrations up to 10 μg/mL, establishing its safety profile for functional assays. Crucially, we then investigated its anti-inflammatory effects in an LPS-stimulated macrophage model, which mimics the inflammatory activation central to UC pathogenesis. Our qPCR results demonstrated that Batatasin-III significantly and dose-dependently inhibited the mRNA expression of key pro-inflammatory mediators, including TNF-α, IL-6, IL-1β, and NOS2. This experimental evidence directly validates our network pharmacology predictions. These cytokines (TNF, IL-6, IL-1β) are central nodes in the inflammatory networks we identified, and the suppression of NOS2 aligns with the modulation of inflammatory pathways such as the MAPK and PI3K-Akt signaling axes, which are known to regulate iNOS expression. Conclusion In conclusion, this study successfully integrates comprehensive network pharmacology, molecular simulation, and in vitro experimental validation to elucidate the mechanism of Batatasin-III against UC. We computationally identified Batatasin-III as a promising multi-target agent, predicting its stable binding to key proteins like MAPK3 and HSP90AA1 and its modulation of critical inflammatory pathways. These hypotheses were then confirmed by our in vitro findings, which demonstrated that Batatasin-III potently suppresses the mRNA expression of TNF-α, IL-6, IL-1β, and NOS2 in LPS-stimulated macrophages without exhibiting cytotoxicity. This convergence of computational prediction and biological evidence provides a robust foundation for Batatasin-III’s therapeutic potential. It suggests that Batatasin-III, a natural phenanthrene derivative, may be a promising lead candidate for future UC therapeutics. While these in vitro results are encouraging, further in vivo studies using established colitis models are warranted to fully confirm its therapeutic efficacy and mechanism of action within a complex biological system.